Predictive Oncology’s Breakthrough in Drug Repurposing Offers Hope for Patients
/0 Comments/in Drug repurposing, Preclinical Research/by MaxAdvancements in Delivery: Gene Therapy Could Help Prostate Cancer Treatment
/0 Comments/in CRISPR, Delivery, Preclinical Research/by MaxNew Molecule Boosts Vaccine Power Against Cancer and Viruses, In Vivo Study
/0 Comments/in Immunotherapy, Preclinical Research/by MaxNew Radiotherapy ATNM-400 Targets Advanced Prostate Cancer
/0 Comments/in Preclinical Research/by MaxAI-Guided Cancer Vaccines Signal a New Era in Personalized Medicine
/0 Comments/in Artificial Intelligence, Immunotherapy, Preclinical Research/by MaxTelomir-1: Innovative Molecule Slows Tumor Growth and Reduces Chemotherapy Toxicity
/0 Comments/in Preclinical Research/by MaxBreaking Resistance: A Dual-Pathway Drug Shows Promise for Advanced Prostate Cancer
/0 Comments/in Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
abiraterone acetate ADC ADT AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Phase 1 Trial: PMR-116, Targeting The Undruggable MYC Oncogene June 16, 2025
- Newsletter 24/2025 June 15, 2025
- Cholesterol Identified as Key Shield in Heat-Resistant Cancer Cells June 13, 2025
- ATRN-119: A New Promising ATR Inhibitor for ATM Mutations (And Other HRR Mutations) June 13, 2025